Effectiveness and safety of tacrolimus ointment combined with dupilumab for patients with atopic dermatitis in real-world clinical practice
Effectiveness and safety of tacrolimus ointment combined with dupilumab for patients with atopic dermatitis in real-world clinical practice
复制标题
他克莫司软膏联合dupilumab治疗特应性皮炎的临床疗效和安全性
DOI：
10.1111/1346-8138.16039
复制
发表时间：
2021
期刊：
影响因子：
3.1
通讯作者：
Kanazawa N
中科院分区：
文献类型：
--
作者：
Matsutani M;Imai Y;Inoue Y;Nakatani-Kusakabe M;Natsuaki M;Yamanishi K;Kanazawa N
特应性皮炎（AD）是影响全世界所有年龄组的人的最常见的炎性皮肤病。据我们所知，目前尚无评估他克莫司软膏和dupilumab联合治疗AD有效性的研究。因此，我们在此描述了他克莫司软膏联合dupilumab治疗AD患者面部皮疹的有效性和安全性。总体而言，我们纳入了2018年4月至2020年7月在兵库医科大学附属医院皮肤科新接受dupilumab治疗的109例患者。其中60例用他克莫司软膏治疗。具体而言，在60例患者中，40例接受dupilumab联合他克莫司软膏和局部类固醇治疗，而其余20例仅接受他克莫司软膏处方并进行进一步分析。分析表明，该组合在高频率下不会引起严重的副作用。患者的面部皮炎沿着全身性皮炎迅速改善，头颈部湿疹面积和严重程度指数（EASI）评分改善率与总体EASI评分改善率显著相关。此外，在这20例患者中未观察到单纯疱疹并发症。因此，他克莫司软膏联合dupilumab是治疗面部AD的有效且安全的治疗选择。
Atopic dermatitis (AD) is the most common inflammatory skin disease affecting people of all age groups worldwide. To our knowledge, there are currently no studies estimating the effectiveness of tacrolimus ointment and dupilumab as a combination therapy for AD. Thus, here we describe the effectiveness and safety of tacrolimus ointment in combination with dupilumab for facial rashes in patients with AD. Overall, we included 109 patients who newly received dupilumab from April 2018 to July 2020 in the Dermatology Department of Hyogo College of Medicine Hospital. Of them, 60 patients were treated with tacrolimus ointment. Specifically, of the 60 patients, 40 were treated with dupilumab in combination with tacrolimus ointment and topical steroids, whereas the remaining 20 were prescribed tacrolimus ointment alone and were further analyzed. The analysis showed that the combination does not cause serious side‐effects at high frequency. The patients showed rapid improvement of facial dermatitis along with systemic dermatitis, and the rate of improvement of head/neck Eczema Area and Severity Index (EASI) score significantly correlated with the rate of improvement of overall EASI score. In addition, there was no complication of herpes simplex observed in these 20 patients. Thus, tacrolimus ointment combined with dupilumab is an effective and safe treatment option for facial AD.